
-
Beam Therapeutics Inc NasdaqGS:BEAM Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Location: 238 Main Street, Cambridge, MA, 02142, United States | Website: https://beamtx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
716.3M
Cash
1.22B
Avg Qtr Burn
-87.85M
Short % of Float
21.90%
Insider Ownership
1.22%
Institutional Own.
82.28%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BEAM-302 Details Alpha-1 Antitrypsin Deficiency | Phase 1/2 Data readout | |
BEAM-101 Details Beta thalessemia, Sickle cell disease | Phase 1/2 Data readout | |
BEAM-201 Details Blood cancer, Cancer, T-cell lymphoma, Acute lymphoblastic leukemia | Phase 1/2 Update | |
BEAM-301 Details Glycogen Storage Disease Type Ia , Gene & Cell therapies | Phase 1/2 Initiation | |
BEAM-103 Details Beta thalessemia, Sickle cell disease | Phase 1 Initiation |